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ABSTRACT   
 
SPROUTY2 (SPRY2) is an intracellular regulator of receptor tyrosine kinase signaling 
involved in cell growth, differentiation and tumorigenesis. Here we show that SPRY2 is a 
target gene of the Wnt/β-catenin pathway that is abnormally activated in more than 90% of 
colon carcinomas. In human colon cancer cells, SPRY2 expression is induced by β-catenin in 
cooperation with the transcription factor FOXO3a instead of TCF/LEF1 proteins. We found 
binding of β-catenin to the SPRY2 promoter at FOXO3a response elements. In vivo, cells 
marked by nuclear β-catenin and FOXO3a express SPRY2 in proliferative epithelial tissues 
such as intestinal mucosa and epidermis. Consistently, inducible β-catenin deletion in mice 
reduced Spry2 expression in the small intestine. Moreover, SPRY2 protein expression 
correlated with nuclear β-catenin and FOXO3a colocalization in human colon carcinomas. 
Importantly, the amount of SPRY2 protein correlated with shorter overall survival of colon 
cancer patients. Our data reveal SPRY2 as a novel Wnt/β-catenin and FOXO3a target gene 
indicative of poor prognosis in colon cancer. 
 
Keywords: SPROUTY2; Wnt pathway; β-catenin; FOXO3a; Colon cancer. 
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INTRODUCTION 
Colorectal cancer (CRC) is the second cause of death by cancer worldwide (1). Constitutive 
activation of the Wnt/β-catenin pathway by mutations is an initiating event in more than 
90% of human CRC (2). In normal tissues without Wnt pathway activation, cytosolic β-
catenin is recruited to a destruction complex that contains the scaffold Axin and 
Adenomatous polyposis coli (APC) proteins, casein kinase α/ε and glycogen synthase kinase 
3β (GSK3β). β-catenin phosphorylation by these two kinases commits it towards 
degradation by the proteasome. When Wnt signaling is activated, the destruction complex is 
disassembled and β-catenin is not phosphorylated, translocating to the cell nucleus where it 
binds the Lymphoid Enhancer Factor/T-Cell Factor (LEF/TCF) family of transcription 
factors. β-Catenin/TCF complexes control the expression of many genes involved in cell 
proliferation and invasion thus promoting tumor initiation and progression (3). 
 In addition, β-catenin has been shown to bind other transcription factors enhancing 
the expression of alternative sets of target genes and directing cell fate in tissue homeostasis, 
development and cancer (4-8). One of these transcription factors is FOXO3a, that induces 
genes responsible for apoptosis, cell cycle arrest and response to oxidative stress (9). 
Furthermore, FOXO3a and TCF/LEF factors compete for the binding of limited amounts of 
nuclear β-catenin as transcriptional co-activator: while nuclear FOXO3a accumulation 
reduces β-catenin/TCF transcriptional activity (10), β-catenin/FOXO3a complexes regulate 
genes involved in longevity and oxidative stress (11). In addition, we recently described that 
nuclear β-catenin and FOXO3a cooperate to induce a complete set of genes involved in 
colon cancer metastasis (8). In this context, we have now evaluated in detail SPROUTY2 
(SPRY2) as a potential target gene of the Wnt/β-catenin pathway by enhancing FOXO3a 
transcriptional activity. Indeed, transcriptome and promoter analyses of mouse endothelium 
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identified Spry2 as a direct FoxO target gene that mediates endothelial cell morphogenesis 
and vascular homeostasis (12).  
SPRY2 expression is downregulated in breast, prostate, hepatocellular carcinoma 
and in B-cell diffuse lymphoma suggesting a tumor suppressive role (13-17). Contrarily, it is 
upregulated in melanoma cell lines concomitantly to N-RAS and B-RAF activating mutations 
(18, 19). Data regarding colon cancer are contradictory. While it was reported that SPRY2 
RNA levels are downregulated in some intestinal tumors (13), we and others have reported 
an increased expression of SPRY2 in high-grade undifferentiated carcinomas as compared to 
normal intestinal mucosa in colon cancer patients (20, 21). Furthermore, SPRY2 reduces the 
expression of the tumor suppressor E-cadherin responsible of retaining cell-to-cell contacts 
and inhibiting cell motility. Contrarily, SPRY2 knockdown diminishes cell invasion in 
human colon cancer cells (20, 21). To help clarifying the role of SPRY2 in cancer, we 
decided to study the molecular mechanisms that control its expression and to analyse its 
potential value as prognostic marker in colon cancer, both relevant aspects that have not yet 
been explored in detail. 
In this study, we reveal that SPRY2 expression is regulated by FOXO3a and β-
catenin nuclear activity. Simultaneous accumulation of both factors in the nucleus induced 
an increase of SPRY2 RNA and protein in colon cancer cells. We detected β-catenin 
recruited to the SPRY2 gene at FOXO3a response elements by chromatin 
immunoprecipitation (ChIP) assays, confirming that it is a direct β-catenin target gene most 
probably through direct FOXO3a binding. Consistently, in normal mouse small intestine and 
human colon tissue, SPRY2 is expressed at the bottom of the crypts, the proliferative 
compartment where Wnt/β-catenin pathway is most active and FOXO3a is accumulated in 
the cell nucleus. Similarly, Spry2 is expressed in cells with nuclear β-catenin and FOXO3a 
proteins in the matrix of mouse hair follicles, a system which growth is well established to 
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be stimulated by Wnt ligands (5, 22). In fact, Spry2 expression is reduced upon inducible 
intestinal deletion of β-catenin in mice, confirming that its expression is dependent on 
Wnt/β-catenin signaling activity in vivo. Furthermore, we found a direct correlation between 
SPRY2 protein expression and nuclear β-catenin and FOXO3a colocalization content in 
human colon carcinomas. Remarkably, SPRY2 expression correlates with shorter overall 
survival of colon cancer patients. Finally, we observed that simultaneous activation of β-
catenin and FOXO3a enhances SPRY2 expression and EGFR/ERK-AKT. 
Together, these data demonstrate that SPRY2 is a Wnt/β-catenin and FOXO3a target 
gene indicative of poor prognosis in colon cancer patients.  
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RESULTS 
SPRY2 is a β-catenin and FOXO3a target gene in colon cancer cells 
To explore the possible regulation of SPRY2 expression by FOXO3a and β-catenin, we 
expressed a 4-hydroxytamoxifen (4OHT)-inducible, AKT-insensitive FOXO3A mutant 
(FOXO3A-ER) (23) and a doxycycline (DOX)-inducible, stabilized (non-degradable) β-
catenin mutant (β-cateninS33Y) in human DLD1 colon cancer cells (DLD1Fß). DLD1 cells 
were chosen for these experiments since they have low basal nuclear FOXO3a or β-catenin 
content and low β-catenin/TCF-driven transcriptional activity (8). Both FOXO3a and β-
catenin proteins accumulated in the nucleus upon corresponding inducible treatments 
(Figure 1a). Exposure to 4OHT or DOX increased SPRY2 RNA amounts and the 
combinatory treatment further induced its expression in DLD1Fβ cells (Figure 1b). The 
increase was also detected at protein level and again it was higher when β-catenin and 
FOXO3a were simultaneously localized in the nucleus (Figure 1c). SPRY2 phosphorylation 
is associated with electrophoretic mobility shift. Two bands are detected for SPRY2 protein 
corresponding to, serine residues phosphorylated form (upper band), and non-
phosphorylated form (lower band). Phosphorylation of SPRY2 likely plays a role in 
determining its stability and function status (24-26). Regulation was specific since the 
expression of Sprouty family member SPRY1 did not increase following 4OHT and/or DOX 
addition. As expected, DOX induced the β-catenin/TCF target LEF1, whose expression was 
reduced by 4OHT-mediated FOXO3a induction probably due to competition for β-catenin 
binding (10). Besides, the expression of the cell cycle regulator p21CIP1, a reported FOXO3a 
target, was induced by 4OHT treatment. The inducible expression of an exogenous dominant 
negative ΔNTCF4 in LS174T colon cancer cells repressed TCF/LEF dependent transcription 
and the expression of target genes like C-MYC or AXIN2 (27), but did not reduce SPRY2 
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expression, indicating that it is not a canonical TCF/LEF target gene (Supplementary Figure 
1a, b). 
We next examined whether β-catenin binds to the SPRY2 gene promoter at putative 
FOXO3a binding sites (DBEs) in DLD1Fβ cells by Chromatin Immunoprecipitation (ChIP) 
assays. Among the nine putative DBEs that we identified across the sequence of the human 
SPRY2 coding and upstream promoter sequences, we only observed enrichment in β-catenin 
precipitation on those sites located next to the transcriptional start site (DBE2 and DBE3) 
(Figure 1d and e). The maximum β-catenin enrichment upon DOX treatment was detected 
1700 bp upstream of the SPRY2 start codon (DBE2) (Figure 1d and e). β-catenin was also 
enriched upon DOX and reduced upon 4OHT (FOXO3a) treatment at TCF binding sites on 
LEF1 promoter (Supplementary Figure 1c) (10).  
Finally, we observed that exogenous nuclear β-catenin induced the activity of 
SPRY2 gene promoter region, extending from -1826 bp to +221 bp, upon DOX treatment in 
DLD1Fβ (Figure 1d, f). This region contained the FOXO3a binding site DBE2 
where β-catenin was most recruited in ChIP assays (Figure 1d, e) 
 
SPRY2 expression in human colon epithelium and epidermis correlates with nuclear 
FOXO3a and β-catenin colocalization 
We next studied the expression of FOXO3a, β-catenin and SPRY2 proteins in human colon 
by immunofluorescence analyses. Whereas FOXO3a was equally accumulated in the 
nucleus of epithelial cells all across the human colon mucosa, β-catenin was nuclear only in 
some epithelial cells at the bottom of the crypts where the Wnt pathway is highly activated 
(Figure 2a-c). Interestingly, SPRY2 protein was also enriched in epithelial cells at the 
bottom of colon crypts, and was found preferentially in the cytoplasm (Figure 2d and e). In 
this same crypt area epithelial cells express high levels of the β-catenin/TCF target CD44, 
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high Ki67, and low cytokeratins, indicating high proliferation and poor differentiation 
(Supplementary Figure 2a-c). In summary, SPRY2 expression was concentrated at the 
bottom of the colon crypts, a region where cells present nuclear FOXO3a and β-catenin, 
Wnt/β-catenin pathway activation (3), high proliferation rate and low differentiation 
(Supplementary Figure 2d). SPRY2 is also expressed in stromal cells surrounding the 
intestinal epithelium. 
We also analysed FOXO3a, β-catenin and Spry2 expression in mouse hair follicles 
in which growth is directly linked to Wnt pathway activation (5, 22). β-catenin and FOXO3a 
colocalized in the nucleus of epithelial cells at the matrix region of the growing anagen hair 
follicles (Supplementary Figure 3a, b). These epithelial cells are directly exposed to Wnt 
ligands secreted by the specialized stromal cells that populate the dermal papilla during the 
anagen hair growth phase (5, 22) (Supplementary figure 4d). Spry2 protein was detected just 
in the same hair matrix region where FOXO3a and β-catenin simultaneously accumulated in 
the cell nucleus (Supplementary figure 3d and e). The expression of CD44 and Lef1 Wnt/β-
catenin target genes was high in this matrix region where β-catenin was nuclear and Spry2 
staining was positive (Supplementary figure 3d and Supplementary figure 4a and b). We 
observed that Spry2 expression coincided with that of keratin Ha1 that is a marker of early 
hair shaft differentiation (Supplementary figure 4c). Finally, we detected an enrichment of 
β-catenin bound to the DBE present at the proximal region of the Spry2 gene promoter, by 
performing ChIP assays with extracts of mouse skin that presented a majority of hair 
follicles at growing anagen phase (Supplementary figure 3c and Supplementary figure 4e). 
In summary, these data indicate that Spry2 is expressed in cells that accumulate 
high levels of nuclear FOXO3a and β-catenin and in their immediate cell offspring in these 
two highly proliferative tissues, human intestinal colon mucosa and mouse growing hair 
follicles (Figure 2g and 3g).  
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Spry2 expression in mouse intestine requires β-catenin 
We extended the study of Spry2 expression to the mouse intestine. Similarly to human tissue 
(Supplementary figure 2c), Spry2 was absent from the differentiated villi and accumulated 
in the proliferative area, colocalizing with Ki67 at the bottom of the intestinal crypts (Figure 
3a). However, Spry2 was predominantly detected at the cell membrane in mouse small 
intestinal tissue, whereas it was mostly cytoplasmic in human colonic intestine (Figure 2d, e 
and 3a, c).  
To determine whether β-catenin is essential for Spry2 expression in vivo we used a 
mouse model of 4OHT-inducible ablation of β-catenin from epithelial cells of the intestine 
(villin-creERT2-β-cateninlox/lox) (28). β-catenin deletion upon 4OHT treatment provoked 
reduced expression of the β-catenin/TCF target CD44 and concomitant downregulation of 
Spry2 expression in the intestinal crypts (Figure 3b-d). Therefore, the activity of β-catenin is 
required for the expression of proper amounts of Spry2 protein at the proliferative mouse 
crypts, similarly to other Wnt targets such as CD44. 
 
SPRY2 expression correlates with nuclear FOXO3a and β-catenin content in colon 
carcinomas and is indicative of shorter patients survival 
We first analysed the correlation of SPRY2 expression with nuclear accumulation of 
FOXO3a and β-catenin in a panel of colon tumors at different stages of progression (Figure 
4a). Most adenomas and a proportion of carcinomas (Patient 1, P1) presented β-catenin 
mostly localized at cell-to-cell contacts and at very low levels in the nucleus. In contrast, 
less differentiated carcinomas (P2, P3) and liver metastases showed high accumulation of 
nuclear β-catenin. Nuclear FOXO3a was detected in adenomas, a subset of carcinomas (P3) 
and liver metastases. In summary, concomitant nuclear FOXO3a and β-catenin 
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accumulation was only found in some advanced carcinomas and liver metastases. 
Interestingly, SPRY2 expression was very high only in these tumors exhibiting co-
expression of FOXO3a and β-catenin in the cell nucleus (Figure 4b). Furthermore, high 
SPRY2 expression corresponded to carcinomas with low cytokeratin staining indicative of 
poor differentiation (Supplementary figure 5). In contrast to SPRY2, high expression of the 
β-catenin/TCF target CD44 correlated with nuclear β-catenin accumulation even in the 
absence of FOXO3a (Figure 4b).  
 SPRY2 expression and nuclear β-catenin and FOXO3a colocalization were 
quantified in 30 human Stage III colon carcinomas (Supplementary table 1). A significant 
correlation (P = 0.0045) existed between SPRY2 expression and the amount of nuclear β-
catenin and FOXO3a colocalization signal (Figure 5a). Most importantly, those patients with 
the highest SPRY2 expression presented a 14-months shorter survival (Low = 36 vs High = 
22 months. P = 0.0237. HR, 0.3892; 95% CI, 1.148-2.125) (Figure 5b). 
 
FOXO3a and β-catenin enhance the EGFR/ERK-AKT pathway 
We investigated the possible role of SPRY2 as a FOXO3a/β-catenin target gene capable of 
regulating EGFR (29-31). First we treated DLD1Fβ cells with EGF during different times 
(from 30 to 180 minutes) either under control conditions or after accumulating nuclear β-
catenin and FOXO3a by pre-treating with DOX+4OHT (Figure 6a, b). The induction of 
nuclear β-catenin and FOXO3a increased SPRY2 and EGFR expression and the 
concomitant activation of pAKT and pERK. Addition of EGF reduced the amount of its 
receptor EGFR by inducing its degradation (29, 31) but simultaneously increased pEGFR, 
pAKT and pERK. Such activation was transient, decaying at later time points. When cells 
were pre-treated with DOX+4OHT, EGF-induced activation of EGFR, AKT and ERK 
equally occurred but signal decay was delayed and persisted longer time. In summary, cells 
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with nuclear FOXO3a and β-catenin presented enhanced amplitude of response to EGF 
signal.  
 To explore the particular relevance of SPRY2 as a FOXO3a/β-catenin target gene 
regulating EGFR, we knocked down its expression by expressing specific shRNAs in 
DLD1Fβ cells and performed the corresponded analysis (Figure 6c and d). We first observed 
that the pool of lentivirus expressing shRNA against SPRY2 decreased its expression to 58% 
upon DOX+4OHT treatment. Next, control (c) and knock down (sh) cells were treated 180 
min with EGF after pre-treatment or not with DOX+4OHT. The limited reduction of SPRY2 
expression promoted a reduction of EGFR and AKT activation upon EGF treatment that was 
not statistically significant. No effect was observed on ERK activation. 
 Finally, we observed that the 4OHT-induced ablation of β-catenin from epithelial 
cells of the intestine in villin-creERT2-β-cateninlox/lox mice promoted the decrease of pEGFR 
level (Figure 6e). Therefore, the activity of β-catenin is required for the proper expression 
and/or activation of EGFR at the proliferative mouse crypts where nuclear FOXO3a, β-
catenin and Spry2 content is high. 
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DISCUSSION 
The mammalian SPRY protein family consists of four members that bind to a variety 
of endogenous kinases, phosphatases and adapter proteins, which allow them to modulate 
the signaling of several growth factor tyrosine kinase receptors (RTK) (32). RTK signaling 
is central in controlling the homeostasis of small intestine and colon epithelia (33). In 
particular, SPRY2 modulates the epidermal growth factor receptor (EGFR) signaling 
pathway (29-31). Upon EGF stimulation of its receptor, the c-Cbl E3 ligase binds and 
ubiquitinates EGFR, targeting it to internalization and destruction by the endocytotic 
machinery. In this scenario, active SPRY2 competes with c-Cbl for the binding to EGFR, 
thus reducing receptor endocytosis and increasing the amplitude and duration of downstream 
Ras/MAPK pathway activation (34-36). SPRY2 also interacts with the hepatocyte growth 
factor (HGF)-regulated tyrosine kinase substrate (Hrs) interfering with the trafficking of 
ligand-activated EGFR receptor from early to late endosomes and thus increasing the 
signaling (37). In contrast, in certain cellular contexts SPRY proteins not only fail to 
enhance but may even inhibit RTK , indicating a complexity of SPRY function that warrants 
further detailed studies (24, 26, 38, 39).  
Although such modulation of RTK signaling could play a relevant role in fundamental 
processes during development, adult tissue homeostasis and cancer initiation or progression 
(33), no data about the regulation of SPRY2 expression was available up to now. 
In this study, we show that nuclear colocalization of FOXO3a and β-catenin induces 
SPRY2 RNA and protein expression in colorectal carcinoma cells. We found that β-catenin 
interacts with two regions on the SPRY2 gene promoter where FOXO binding sequences are 
located, but which lack response elements for TCF/LEF or other transcription factors that 
interact with β-catenin. Besides, β-catenin enhances the activity of the proximal promoter 
region of SPRY2 gene. Altogether these data indicate that SPRY2 is a FOXO3a and β-
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catenin target gene induced through the recruitment of both factors to specific regulatory 
gene regions. It remains unknown whether FOXO3a and β-catenin would form part of the 
same regulatory protein complex on the SPRY2 gene promoter or would act independently. 
In vivo, we have identified high SPRY2 expression in a subpopulation of Wnt/β-
catenin-activated epithelial cells that also accumulate nuclear FOXO3a, either at the bottom 
of human intestinal crypts or in the matrix of mouse anagen hair follicles. SPRY2 expression 
is extended to the immediate offspring of proliferative cells activated by FOXO3a and β-
catenin. These results together with the loss of Spry2 expression in the small intestine of β-
catenin null mice, confirm SPRY2 as a β-catenin target gene.  
Interestingly, the same cell populations at the bottom of the intestinal crypts and the 
matrix of the growing hair follicles expressing SPRY2 are highly activated by EGF ligands 
(40). It is therefore possible that SPRY2, as a FOXO3a/β-catenin target gene, could be a key 
factor modulating the crosstalk between Wnt/β-catenin and EGF signaling pathways in vivo. 
The cell populations located within these regions contain adult stem and progenitor cells, 
and both Wnt and EGF signals from the corresponding specialized niches are fundamental to 
sustain their distinct pluripotency and self-renewal capacities (28, 41-43). Further studies 
that include the analysis of conditional tissue specific Spry2 null mice should be performed 
to reveal its possible role in the physiology of adult stem cells and for the homeostasis of 
epithelial tissues. 
 Indeed, mice carrying Spry2 null alleles die as a consequence of gastrointestinal 
abnormalities at postnatal day 21-28 (44). Although these data evidence that Spry2 is crucial 
for intestinal homeostasis, its exact role for intestinal stem cells physiology remains to be 
analysed. Other processes dependent on the Wnt/β-catenin pathway like limb, lung or 
kidney development are perturbed in vertebrates overexpressing the SPRY2 gene (44). 
Altogether, these data suggest that the tight control of the precise amounts of SPRY2 by the 
 14
Wnt/β-catenin pathway could be essential for an orderly execution of different biological 
processes during development or the homeostasis of various adult tissues. 
Abnormal activation of the Wnt/β-catenin pathway by mutations, that promote nuclear 
accumulation of β-catenin, is an initiating event in more than 90% of colon cancer patients. 
Contrarily, FOXO3a is considered a tumor suppressor since it can promote cell cycle arrest 
and apoptosis in cancer cells. Indeed, the combined knockdown of FOXO1, 3, and 4 in mice 
is responsible for tumor initiation (12). However, we have recently demonstrated that the 
accumulation of high amounts of both FOXO3a and β-catenin in the nucleus of cancer cells 
imposes a high motile phenotype promoting metastasis in mice and correlating with 
metastatic stages and shorter overall survival of colon cancer patients (8). Similarly, we 
describe here that high levels of SPRY2 also correlate with shorter survival of colon cancer 
patients. Furthermore, supporting the idea of SPRY2 as an oncogene we previously showed 
its capacity to increase the expression of ZEB1, an inducer of epithelial-to-mesenchymal 
transition, which promotes cell migration and invasion in colon cancer cells (20). 
In this scenario, SPRY2 could play a role in the malignant phenotype of colon cancer 
cells as a β-catenin and FOXO3a target gene. Its activity could also modulate EGF signaling 
which in fact is central in many colon carcinomas. Indeed, the use of anti-EGFR antibodies 
such as Cetuximab has become one of the most important clinical strategies to treat K-RAS 
wild type patients with advanced metastatic disease. Therefore, SPRY2 expression could be 
used to determine the response to Cetuximab as previously suggested (45).  
Our data provide a better understanding of the consequences of Wnt/β-catenin 
pathway activation by including SPRY2 as a new target gene which may modulate other 
signaling pathways like EGFR, relevant for tissue homeostasis and tumor progression. In 
fact, we observed a decrease in pEGFR content in mouse colon intestines knocked out for β-
catenin, indicating the interplay of both pathways in vivo. 
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The limited effects of SPRY2 knock down on EGFR signaling could indicate that 
FOXO3a and β-catenin increase the amplitude of EGFR signaling by regulating other 
factors. Indeed, we previously described that β-catenin and FOXO3a regulate the expression 
of multiple common target genes involved in cell signaling, proliferation and malignancy in 
colon cancer. Further investigations would be required to identify which are the FOXO3a/β-
catenin target genes others than SPRY2 that determine such enhanced EGFR signaling. 
However, since in our experiments the expression of SPRY2 was only reduced by 58%, it is 
also possible that a more efficient knock down of SPRY2 expression may be necessary to 
detect an effect on the induction of EGFR signaling by FOXO3a and β-catenin. 
Furthermore, our data suggest that β-catenin and FOXO3a could execute part of their 
oncogenic activity by sustaining an enhanced EGFR-RAS-ERK/AKT signaling. Such 
mechanism could determine tumor malignancy and progression since the EGFR signaling 
drives central aspects of the cancer cell phenotype: hyperproliferation, enhanced survival, 
motility or migration. 
We found that SPRY2 is the only member of its family upregulated by β-catenin and 
FOXO3a. Such results are in line with previous evidences showing SPRY2 as the only 
member upregulated in colon cancer tumors compared with adjacent normal mucosa (21). 
Altogether these data highlight the relevance of SPRY2 in colon cancer malignancy. In 
summary, our results reveal SPRY2 as a new β-catenin and FOXO3a target gene that is 
expressed in Wnt-activated cells in normal and tumoral tissues and correlates with shorter 
overall survival of colon cancer patients. It should therefore be considered as a prognosis 
marker and a potential target to direct therapeutic intervention in the future. 
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MATERIALS AND METHODS 
 
Cells, culture and treatments 
DLD1 human colon cancer cells were cultured in DMEM plus 10% foetal bovine serum 
(Invitrogen). Cells were transfected with pcDNA-FOXO3A:ERTM (46) and neomycin-
selected to obtain a clone of DLD1F cells. β-CateninS33Y was introduced in DLDF cells by 
infection with pSIN-TRE-flag-β-cateninS33Y-IRES-GFP lentivirus to generate the DLDFβ 
cell line. Lentiviral particles were produced by transfecting 293T cells with lentiviral 
construct and packaging vectors (pPAX2 and pMD2.G, Addgene) (8) . Cells were treated as 
follows: 2.5 µg/ml Doxycycline (DOX, Sigma-Aldrich) for 12 h before 50 nM 4-
Hydroxytamoxifen (4OHT, Sigma-Aldrich) for 24 h. In experiments using EGF, cells were 
treated with DOX (same concentration) for 24 h before an additional 16 h incubation in 
serum-free medium in the presence of DOX and 4OHT (same concentrations), prior to the  
treatment with EGF (100 ng/mL) or vehicle. 
SPRY2 knock down was performed in DLD1Fβ cells by infecting simultaneously with eight 
different lentivirus expressing shRNAs specific against human SPRY2 mRNA (Open 
BioSystems) and following previously described protocols (8). DLD1Fβ cells infected with 
lentivirus expressing control non-silencing shRNA were use as control. 
 
Mice 
β-Catenin ablation was induced by intraperitoneal injection of 1 mg of tamoxifen (Sigma-
Aldrich) per 20 g of body weight into 10-week-old β-catenin -villin-creERT2 (28) mice, for 
4 consecutive days before analysis.  Both inducible mutant (β-cateninlox/lox-villin-creERT2) 
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and control (β-catenin+/lox-villin-creERT2) animals were injected according to the same 
regimen.  
Quantitative RT-PCR 
Total cellular RNA was purified using RNeasy mini kit (Qiagen). Values were normalized 
versus housekeeping gene succinate dehydrogenase complex subunit A (SDHA). The 
reaction was performed in a Light-Cycler apparatus using the LightCycler-FastStart DNA 
MasterPLUS SYBR Green I Kit (Roche Diagnostics) or the High Capacity cDNA Reverse 
Transcription Kit, TaqMan SPRY2 Hs00183386_m1 and TaqMan Universal PCR Master 
Mix, no Amperase, (Applied Biosystems). All experiments were performed by triplicate  
 
 
Western blotting 
 
Whole-cell extracts were prepared by washing the monolayers twice in PBS and cell lysis by 
incubation in RIPA buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 10% 
glycerol, 4 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% deoxycholate) plus phosphatase 
and protease-inhibitor mixture (25 mM β-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 
1mM PMSF, 10 μg/ml leupeptin, 10 μg/ml aprotinin) for 15 min on ice followed by 
centrifugation at 13,000 rpm for 10 min at 4ºC. Western blotting of cell lysates was 
performed by electrophoresis in SDS-PAGE and protein transfer to Immobilon P 
membranes (Millipore). The membranes were incubated with the appropriate primary and 
secondary horseradish peroxidase-conjugated antibodies, and the antibody binding was 
visualized using the ECL detection system (GE Healthcare, Chalfont St Giles, UK). 
Different exposure times of the films were used to ensure that bands were not saturated. 
Quantification of the films was performed by densitometry using ImageJ software 
(Bethesda, MD, USA). 
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Chromatin Immunoprecipitation and sequence analysis 
Chromatin Immunoprecipitation was carried out as described previously (47) using β-
catenin (BD Bioscience, Oxford, UK) or a species matched IgG control (Millipore) and 
LEF1 and SPRY2 promoter-specific primers. Previously described sequences of FOXO3a 
response elements (DBE) in the mouse Spry2 gene were identified in the homologous 
human SPRY2 gene using NTI software and primers were designed accordingly for the ChIP 
analysis. Identification of putative response elements of other transcription factors able to 
interact with β-catenin on the SPRY2 gene sequence, was performed by TRANSFAC 
software. We used a set of primers to analyse TCF/LEF binding sites in the human LEF1 
gene (48). Primer sequences were as follows: Spry2 A, forward 
GTTTCCAGTCCTTCAAGCAATC, reverse AATTGGGAGTGGCTGTAACAAA; Spry2 
B, forward GGTAGACTTGAAATGGATTCTGG, reverse 
ACTAATCTGGGCCACGCAGT; Spry2 C, forward CTCTCTCTCTTCCGTTCTTCGT, 
reverse CGCTTGATGACTTTCTTCCTG; Spry2 D, forward 
TTCTCCAGAGAGAATGTGCTATATTT, reverse TCACATTCTTCCGAATGTACAAC, 
Spry2 E, forward CCCAAGAGATGTTTGTCTCTGAC, reverse 
AGTCCAGGTGACATCAAGACCTA, Lef1 F, forward 
TTCTTGGCAAACTTCTCTTTCTC, reverse CTCGAGGCTCATTTAATCTGCTA; Lef1 
G, forward TGGACGTTTCGTTATCTTCTGAT, reverse 
GGATGCCGACTTAGTAGTTTGTTT.  
 
Luciferase assays 
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Cells were transfected using the X-tremeGENE HP DNA reagent (Roche). In transient 
transfections, Firefly (Luc) and Renilla reniformis luciferase (Rluc) activities were measured 
separately using the Dual Luciferase reagent kit (Promega) and a Centro XS3 LB960 
luminometer (Berthold). Luc activity was normalized to the Rluc activity. The SPRY2 
promoter activity was studied using the pGL-hSPRY2-Luc (-1826/+221) construct (49). To 
study β-catenin/TCF transcriptional activity we used the TOP-Flash and FOP-Flash 
plasmids containing multimerized wild-type (CCTTTGATC) or mutated (CCTTTGGCC) 
TCF/LEF-1 binding sites upstream of a minimal c-fos promoter driving luciferase gene 
expression (50) (a gift from Dr. H. Clevers, Utrecht, The Netherlands).  
 
Immunofluorescence and confocal microscopy 
Cultured cells were fixed in methanol at -20ºC for 3 min and then washed four times in PBS. 
Cells were incubated with the primary antibodies diluted in PBS/3% BSA O/N at 4ºC. After 
four washes in PBS, the cells were incubated with secondary antibodies for 45 min at room 
temperature, washed three times in PBS and mounted using Prolong Gold antifade reagent 
(Molecular Probes-Invitrogen). Conventional fixed and paraffin-embedded sections of 
human Stage III CRC tumors from a collection available in the Pathology Service of the 
Vall d´Hebron Hospital were prepared and immunolabelled as described elsewhere (22). 
Briefly, antigens were retrieved by microwaving in 10 mM citrate buffer (pH 6.0) for 10 min 
and permeabilized with 0.2% Triton X-100 (Sigma-Aldrich). Non-specific binding was 
blocked by incubating the sections in 10% BSA (Sigma-Aldrich) for 1 h. Cell imaging was 
performed on a Leica TCS SP5 DMI6000 microscope using argon ion (488 nm), HeNe (543 
nm) and violet diode (405 nm) lasers. Images were acquired sequentially by direct register 
using Leica Confocal Software (LAS AF). Fluorescence images were analysed and 
quantified with the MBF "ImageJ for Microscopy" program (www.macbiophotonics.ca) 
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using criteria described earlier (8, 20) (Arqués, O. et al. "Standardized Relative 
Quantification of Immunofluorescence Tissue Staining". Protocol Exchange. 2012). 
 
Isolation of intestinal crypts 
Freshly isolated small intestines of villin-creERT2-β-catenin were incised along their length 
and villi were removed by scraping. The tissue was then incubated in PBS/EDTA pH=8 
(2mM) for 5 minutes at 4ºC. Gentle shaking removed remaining villi and intestinal tissue 
was subsequently incubated in PBS/EDTA pH=8 for 30 minutes at 4ºC. Subsequently, cells 
were spun down, resuspended in PBS/FBS 5% and filtered through 70-mm mesh.  
 
Antibodies  
We used primary antibodies against β-catenin and EGFR (BD Transduction Laboratories), 
SPRY2 (Abnova, Upstate), C-MYC (9E10, Sigma-Aldrich), AXIN2 ab32197 (Abcam) 
SPRY1 (Abcam), Pan-cytokeratin (Novocastra), β-actin sc-1616, Lamin B sc-6216, AKT 
sc-1618, pERK sc-7383, ERK2 sc-154 (Santa Cruz Biotechnology), CD44 (Ab4, Thermo 
Scientific), CD44-6v (Bender Med. Systems ABIN 123916), LEF1 #C18A7, pAKT #9271, 
pEGFR #3777 (Cell Signaling), EGFR (phospho Y1068), p21CIP (Millipore), Ki67 (MiB-1, 
Dako) and Ha1 (Progen). Secondary antibodies used: Alexa 488-conjugated goat anti-mouse 
and goat anti-rabbit IgG (H + L) (Molecular Probes) and Alexa 546-conjugated goat anti-
mouse, goat anti-rabbit, and goat anti-rat IgG (H + L) (Molecular Probes). Nuclei were 
stained using DAPI or Hoechst 33342 (Molecular Probes).  
 
Statistical analysis 
Significant difference between groups of values in RT-PCR (Figure 1b), Western blot 
(Figure 1c) or ChIP (Figure 1e) assays were calculated by non-parametric ANOVA analysis 
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with Kruskal-Wallis test and quantified by Dunn´s multiple comparison post-tests. 
Difference between values in promoter luciferase assays were analysed by a non-parametric 
t test. We calculated correlation coefficients (r) with two-tailed non-parametric Spearman 
tests which make no assumption about the distribution of the values to compare fluorescent 
signal values of different proteins in patients´ tissue samples (Figure 6a). We analysed 
survival of patients by the Kaplan-Meier method and compared the curves using a Log-rank 
(Mantel-Cox) test assuming that hazard function is the same at all times (Figure 6b). We 
considered significant P values lower than 0.05. 
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FIGURE LEGENDS 
Figure 1. SPRY2 expression is induced by nuclear β-catenin and FOXO3a. (a) 
Immunofluorescence analysis of FOXO3a (green) and β-catenin (red) expression in DLDFβ 
cells treated with DOX and/or 4OHT. Nuclei were stained with Hoechst 33342 (blue). 
Dashed lines mark nuclei positive for FOXO3a and/or β-catenin.  Scale bar, 50 μm. (b) 
Normalized SPRY2 RNA levels in DLDFβ cells treated with DOX and/or 4OHT were 
measured by real-time RT-PCR. Mean ± SD of five independent experiments. P value for 
non-parametric ANOVA analysis with Kruskal-Wallis test is indicated. Asterisk marks 
significant difference between groups quantified by Dunn´s multiple comparison test. (c) 
Protein levels of SPRY1 and 2, LEF1 and p21CIP1 in DLDFβ cells treated with DOX and/or 
4OHT were estimated by Western blot. Lamin B served as loading control. Black arrowhead 
indicates phosphorylated SPRY2 and grey arrowhead indicates non-phosphorylated SPRY2. 
Lower panel shows quantification of six independent experiments, mean ± SD. Black bars 
correspond to the quantifications of phosphorylated and grey bars to non-phosphorylated 
SPRY2 protein. P value for non-parametric ANOVA analysis with Kruskal-Wallis test is 
indicated. Asterisk marks significant difference between groups quantified by Dunn´s 
multiple comparison test. (d) Scaled diagram representing human SPRY2 gene. The nine 
putative FOXO3a-binding elements (DBE) are indicated. qPCR amplified regions (A, B, C 
and D) that cover different DBE and a downstream control region (dsCtrl, E) are shown. 
Exons are represented as grey bars. Yellow bar indicates the promoter region tested by 
luciferase assays in panel f. (e) Graph representing the quantification by qPCR of β-catenin 
enrichment upon ChIP assay on DBE sequences identified in the human SPRY2 gene. 
Values are ordered by amplified region in SPRY2 gene (A to D) and cells treatments are 
indicated. All values correspond to specific β-catenin enrichment versus precipitation with 
control IgG and amplification of an unrelated downstream control region (dsCtrl). (f) 
 24
Activity of SPRY2 gene promoter region tested in DLD1Fβ cells treated as indicated. Bars 
represent the mean ± SD of four replicates. Luciferase reporter gene was under the control of 
SPRY2 gene promoter region extending from -1826 bp to +221 bp from transcription starting 
site. Region tested is shown in the diagram in panel d (yellow bar). Values of luciferase are 
relative to Renilla activity. P value corresponds to non-parametric t test. (b, c, e, f) Relative 
units (r. u.). 
 
Figure 2. SPRY2 is expressed in cells that accumulate nuclear FOXO3a and β-catenin 
at the bottom of the crypts in human colon epithelium. (a) Representative picture 
showing protein expression by double immunofluorescence and confocal microscopy of 
FOXO3a (green), β-catenin (red) and colocalization (yelow). Insets below show 
magnifications with split or merged channels corresponding to an area at the bottom of the 
crypt delineated by a dashed square on the main picture. Dashed lines in insets mark four 
nuclei with the highest double β-catenin and FOXO3a co-localization signal (yellow). (b) 
Image representing nuclear β-catenin and FOXO3a colocalization at the region shown in the 
inset of panel a. Dashed lines mark nuclei with double staining for β-catenin and FOXO3a. 
(c) Colour scatter plot showing the corresponding intensity correlation analysis of green 
(FOXO3a) and red (β-catenin) channels of the nuclei mark by dashed lines in panel b. 
Yellow dots represent co-localization signal. (d, e) Representative picture showing protein 
expression by double immunofluorescence and confocal microscopy of (d) β-catenin (green) 
and SPRY2 (red) or (e) FOXO3a (green) and SPRY2 (red). Insets below show 
magnifications with split or merged channels corresponding to an area at the bottom of the 
crypt delineated by a dashed square on the main picture. SPRY2 expression is pointed by 
arrows in intestinal and by asterisks in stromal cells. (a, d, c). Nuclei were stained with 
Hoechst 33342 (blue). Scale bars, 50 μm. 
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Figure 3. Tissue-specific deletion of β-catenin decreases Spry2 expression in mouse 
intestinal epithelium. (a) Double immunofluorescence staining reveals cells expressing 
Spry2 (green) located at the proliferative region (Ki67, red) of mouse small intestinal crypts 
pointed by white arrowheads. Magnifications below show that Spry2 expression is high in 
Ki67 positive cycling cells at the intestinal crypts pointed by white arrows.  White arrows 
point Ki67 and Spry2 double positive cells shown in the magnifications. (b) β-catenin 
deletion was induced in β-cateninlox/lox-villin-creERT2 mice by tamoxifen injection; β-
catenin+/lox-villin-creERT2 mice were used as a control. Immunohistochemical staining of 
murine small intestine for β-catenin and the Wnt target CD44 show a decrease in the 
expression of both proteins upon treatment. Dashed squares mark the crypts were Wnt 
activity is enhanced. (c) Double immunofluorescence analysis show the lost of β-catenin 
(red) and the reduction of Spry2 (green) in the crypts of the small intestine in β-cateninlox/lox-
villin-creERT2 mice four days after tamoxifen treatment. White arrowhead point to 
intestinal crypts. (a,c) Nuclei were stained with Hoechst 33342 (blue). Asterisks indicate 
stromal cells expressing Spry2. Dashed lines delineate the epithelium-stroma edge. (a-c) 
Scale bars: 50 µm. (d) Western blots showing the expression of β-catenin and Spry2 
proteins in the crypts of the small intestine in β-cateninlox/lox-villin-creERT2 and control 
mice four days after tamoxifen treatment. β-actin was used as loading control. 
 
Figure 4. SPRY2, nuclear β-catenin and FOXO3a expression in human colon cancer. 
(a) Representative pictures of double immunofluorescence staining and confocal analysis of 
β-catenin (red) and FOXO3a (green) in a human colon adenoma, three colon carcinomas 
(P1-P3) and a liver metastasis. Dashed squares delineate areas shown as magnifications 
below to visualize nuclear FOXO3a and β-catenin colocalization. (b) Representative 
pictures of immunofluorescence staining and confocal analysis of CD44 or SPRY2 
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expression (green) in the same panel of patients. The asterisks correspond to SPRY2 
staining in stromal cells. Nuclei were stained with Hoechst 33342 (blue). Scale bars: 100 
µm.  
 
Figure 5. SPRY2 expression correlates with nuclear FOXO3a and β-catenin 
colocalization signal. The expression of  β-catenin, FOXO3a and SPRY2 proteins was 
analysed by immunofluorescence and confocal microscopy in serial tissue sections of 30 
colon carcinoma patients. Quantification was performed as described in Material and 
methods. Relative expression values are show in Supplementary Table 1. (a) Scatter plot 
showing the correlation between nuclear FOXO3a and β-catenin colocalization signal and 
SPRY2 content for each patient. P value corresponds to a Spearman test. (b) Kaplan-Meier 
survival analysis of colon cancer patients separated into two groups by the median for 
SPRY2 signal. Higher signal is in red (n = 14) and lower signal in black (n =16). P values by 
Log-rank (Mantel-Cox) test. 
 
Figure 6. FOXO3a and β-catenin regulate EGFR. (a) Western blots showing the 
expression levels of the indicated proteins in DLD1Fβ cells, pre-treated 24 h with DOX and 
an additional 16 h incubation in serum-free medium in the presence of DOX and 4OHT, 
prior treatment with EGF during the indicated times. (b) Plots representing the 
quantification of the indicated proteins measured by Western blot (panel a) at different 
treatment time points. Values correspond to the mean ± SD of three independent 
experiments. Each value was corrected by the corresponding protein expression at time 0 in 
cells treated or not with EGF. (c) DLD1Fβ cells were infected with a pool of lentivirus 
expressing eight different shRNA against SPRY2 mRNA (sh) or an scramble shRNA 
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(control) (c). The expression of the indicated proteins was evaluated by Western blot in both 
types of DLD1Fβ cells (c and sh) treated 180 minutes with DOX+4OHT and or EGF. (d) 
Graphs representing the quantification of the indicated proteins measured by Western blot 
(panel c). Values were corrected by the expression of each protein in DLD1Fβ cells infected 
with sh scramble control and treated with vehicle. Reduction of SPRY2 expression is 
indicated as percentage of expression in sh-SPRY2 cells versus sh-scramble control cells. 
Bars correspond to the mean ± SEM of two independent experiments. (b, d) Relative units 
(r. u.). (e) β-catenin deletion was induced in β-cateninlox/lox-villin-creERT2 mice by 
tamoxifen injection; β-catenin+/lox-villin-creERT2 mice were used as a control. 
Immunohistochemical staining of murine small intestine for β-catenin (green) and the 
pEGFR (red) show a decrease in the expression of both proteins upon treatment. Nuclei 
were stained with Hoechst 33342 (blue). Asterisks indicate unspecific staining in the crypt 
lumen. Scale bar, 100 μm. 
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Supplementary Figure 1. SPRY2 is not a β-catenin/TCF target gene. (a) Graph 
representing β-catenin enrichment in the two TCF/LEF binding sites (A and B) described for 
the human LEF1 gene (48). All values correspond to specific β-catenin enrichment versus 
precipitation with control IgG and amplification of an unrelated downstream control region 
(dsCtrl). (b) Graph representing the Luciferase activity under the control of four TCF 
response elements (TOP-flash) in LS174T-tetON-ΔNTCF4 colon cancer cells treated as 
indicated. Values were corrected by the activity of a mutant version of the luciferase 
construct in which the response elements can not bind TCF transcription factors (FOP-
flash). Bars correspond to the mean ± SD of three independent experiments. (c) Total 
extracts of LS174T-tetON-ΔNTCF4 colon cancer cells were analysed by Western blot to 
detect the levels of C-MYC, AXIN2 and SPRY2 proteins upon treatment with DOX. Fold 
change of DOX-treated versus non treated cells is indicated for the amount of both proteins 
and corrected by β-actin expression. 
 
Supplementary Figure 2. SPRY2 is expressed in cells at the proliferative, non-
differentiated and Wnt active region at the bottom of the colon crypts. (a-c) 
Representative pictures showing protein expression by double immunofluorescence and 
confocal microscopy of (a) SPRY2 (green) and CD44 (red), (b) PanCytokeratin (green) and 
SPRY2 (red) or (c) Ki67 (green) and SPRY2 (red). (a). Insets below show magnifications 
corresponding to an area at the middle (1) or at the bottom (2) of the crypt that are delineated 
by dashed squares on the main picture. Asterisks indicate SPRY2 positive staining in 
stromal cells. Nuclei were stained with Hoechst 33342 (blue). Scale bars, 50 μm. (d) 
Diagram representing the spatially-organized cell expression of SPRY2, nuclear FOXO3a 
 29
and β-catenin in coordination with Wnt/β-catenin pathway activity, cell proliferation and 
differentiation along the self-renewing human colon crypts. 
 
Supplementary figure 3. Spry2 expression in mouse epidermis correspond to cells that 
accumulate nuclear FOXO3a and β-catenin in growing anagen hair follicles. (a) 
Representative pictures showing protein expression by double immunofluorescence and 
confocal microscopy of FOXO3a (red) and β-catenin (green). Thick dashed lines mark hair 
matrix region (M). Insets below show magnifications corresponding to an area delineated by 
a dashed square on the main picture. Dashed lines in insets mark four nuclei with the highest 
double β-catenin and FOXO3a co-localization signal (yellow). (b) Left panel, image 
representing nuclear β-catenin and FOXO3a co-localization at the region shown in the inset 
of panel a. Dashed lines mark nuclei with double staining for β-catenin and FOXO3a. Right 
panel, colour scatter plot showing the corresponding intensity correlation analysis of green 
(β-catenin) and red (FOXO3a) channels of the nuclei mark by dashed lines in panel b. 
Yellow dots represent co-localization signal. (c) Quantification by qRT-PCR of a ChIP 
assay to detect the enrichment of β-catenin at the DBE sites (B and C) described at the 
proximal region of the mouse Spry2 gene promoter (Figure 1d). The ChIP was performed on 
an extract obtained from mouse back skin rich in growing anagen hair follicles 
(Supplementary Figure 4e). Mean ± SD of three independent experiments. P value 
corresponds to non-parametric t test (d, e) Representative pictures showing protein 
expression by double immunofluorescence and confocal microscopy of (d) β-catenin (green) 
and Spry2 (red) or (e) FOXO3a (green) and Spry2 (red). Insets below show magnifications 
corresponding to an area delineated by a dashed square on the main picture. Dashed lines in 
the insets mark the nuclei of cells that express cytoplasmatic Spry2 and nuclear (d) β-catenin 
or (e) FOXO3a in the hair matrix. (a, d, e) Merge signal from green and red channels is 
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shown in yellow. Nuclei were stained with Hoechst 33342 (blue). (a, b, d, e) Scale bars, 100 
μm. 
 
Supplementary Figure 4. Spry2 is expressed in Wnt-activated cells at the matrix of 
anagen hair follicles. Representative pictures showing protein expression by double 
immunofluorescence and confocal microscopy of (a) Spry2 (green) and Lef1 (red), (b) 
Spry2 (green) and CD44 (red) or (c) Ha1 (green) and Spry2 (red). (a-c) Merge signal from 
green and red channels is shown in yellow. Nuclei were stained with Hoechst 33342 (blue). 
(d) Haematoxylin and Eosin staining of a mouse anagen hair follicle. In this phase, hair 
follicles are stimulated by Wnt ligands secreted by dermal papilla cells (DP) that promote 
accumulation of nuclear β-catenin and proliferation of adjacent epithelial hair follicle matrix 
cells (red line). A sub-population of cells within this Wnt/β-catenin activated domain, also 
accumulate nuclear FOXO3a (white line). Spry2 positive cells correspond to those that 
simultaneously accumulate nuclear β-catenin and FOXO3a and their immediate offspring 
(dashed green line). (h) Haematoxylin and Eosin staining of mouse back skin 30 days after 
shaving. (a-e) Scale bars, 100 μm. 
 
Supplementary Figure 5. SPRY2 expression and Pan-cytokeratin levels in human colon 
cancer. The expression of SPRY2 and cytokeratins (PanCK) was analysed by 
immunofluorescence and confocal microscopy in serial tissue sections of those same 
patients shown in Figure 5. Nuclei were stained with Hoechst 33342 (blue). Scale bars: 100 
µm.  
 
Supplementary table 1. Clinico-pathological information of 30 stage III CRC patients 
analysed for nuclear FOXO3a/β-catenin, and SPRY2 content. Age, sex, lymph nodes 
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affected (L. N.), tumor grade (G1-3), overall survival (months) and tumor expression of 
SPRY2 and nuclear FOXO3a/β-catenin are indicated for the 30 CRC patients studied. The 
upper 16 patients were scored as high and the lower 14 as low SPRY2 expressing. The cut-
off was the median value obtained for the relative SPRY2 expression in all 30 patients 
analysed. 
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